Project Grant R01AG089122
Award Date
9/30/24
Completion Date
5/31/29
Dollars Obligated
$1.7M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The research will use...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $4,472,279 to evaluate the safety and immunogenicity of a preventive tau vaccine, AV-1980R/A, in cognitively unimpaired individuals with preclinical Alzheimer's disease. The 5-year award, effective August 1, 2025, will enable the development of an effective preventive vaccination strategy for future clinical trials. The awardee, Institute For Molecular Medicine Inc., will conduct a...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,754 to Nuravax, Inc. to evaluate the safety, tolerability, and immunogenicity of their adjuvanted preventive dual AB/tau vaccine, DUVAX, in healthy human volunteers. The award will fund a randomized, double-blind, placebo-controlled study to assess DUVAX's safety and ability to generate an immune response in participants aged 40-65. This research builds on preclinical studies...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This federal Project Grant award of $513,740.00 was provided by the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), to develop a novel exosome-based nano-scavenger (EBNS) for the targeted removal of amyloid-beta (Aβ) proteins associated with Alzheimer's disease (AD) and other amyloid-related disorders. The 3-year project aims to: 1) genetically engineer exosomes to load Aβ-targeting antibodies and Aβ-degrading enzymes; 2) establish isolation and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Notre Dame provides $553,998.00 to develop a platform for discovering functional epitopes of the tau protein, which is implicated in several neurodegenerative diseases. The key objectives are to: 1) synthesize a library of conformationally-constrained macrocyclic peptides that mimic pathological tau folds, 2) evaluate the ability of these "mini-tau" peptides to seed...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant (CFDA 93.866 - Aging Research) to Florida International University to develop biotherapeutic nanogels for the treatment of Alzheimer's disease. The goal is to create a novel nanogel system that can effectively cross the blood-brain barrier, inhibit amyloid-beta aggregation, and reduce oxidative stress and neuroinflammation associated with Alzheimer's. The project will focus on improving the nanogel formulation for enhanced...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
This $999,822 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Aeton Therapeutics Inc. supports the development of an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key objectives are to: Evaluate the effectiveness of Aeton's lead candidate, AT-01, in treating neural cells and organoids in vitro compared to another anti-tau antibody, HJ8.7. Determine the efficacy and safety of AT-01 versus HJ8.7 in a mouse model of tauopathy, while...